The LEOPARD (Looking at EVAR Outcomes by Primary Analysis of Randomized Data) trial is the first randomized controlled trial (RCT) comparing the outcomes of endovascular aneurysm repair (EVAR) using commercially available devices in a real-world population. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device […]
Tag: Endologix
ELEVATE IDE Study highlights the Safety and Effectiveness of the ALTO® Abdominal Stent Graft System in One-year Results; Data to Be Presented at 2022 VEITHsymposium
The Endologix ALTO Stent Graft System treats abdominal aortic aneurysms (AAA) with a success rate of 96.7% at 12 months as observed in ELEVATE IDE Study IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving […]
Endologix Submits Premarket Approval (PMA) Application to FDA for the DETOURTM System.
FDA to Review First-of-Its-Kind Percutaneous Femoropopliteal Bypass System IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing disruptive therapies for the interventional treatment of vascular disease, today announced the submission of […]
Endologix Receives CE Mark Certification under EU-MDR for AFX®2 Endovascular AAA System
The AFX2 System integrates anatomical fixation into aortic endografts with an advanced delivery system to treat patients with abdominal aortic aneurysm (AAA). IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives with innovative […]
Endologix Reports 12 Month Data from DETOUR 2 Clinical Trial at 2022 Vascular Annual Meeting
The DETOUR 2 study is a prospective, single-arm, international, multi-center clinical evaluation of the novel DETOUR™ System for fully percutaneous femoropopliteal bypass procedures. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives with […]
Dr. Stephen J. Hoenig Completes First-of-its-Kind Procedure at The Vascular Care Group, Leominster
Minimally invasive procedure decreases recovery time and demonstrates new opportunities in outpatient care LEOMINSTER, Mass.–(BUSINESS WIRE)–The Vascular Care Group (TVCG), a state-of-the art practice committed to the prevention, diagnosis and treatment of vascular disease, today announced Stephen J. Hoenig M.D. successfully […]
Endologix Announces Completion of Enrollment in the TORUS 2 Study for PAD in SFA
The TORUS 2 study is a prospective, single-arm trial of 188 patients to evaluate safety and effectiveness of the TORUS Stent Graft System in the treatment of PAD in the SFA and proximal popliteal arteries IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a […]
Endologix Names Dr. Matthew Thompson President and CEO
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease, announced today the appointment of Dr. Matthew Thompson, as President and Chief Executive […]
Endologix Initiates Randomized Study of ALTO® Abdominal Stent Graft System
JAGUAR Study Evaluates ALTO Compared to Other Commercially Available EVAR Devices IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a leader in the treatment of vascular disease, today announced that the first patient has been enrolled in the company’s JAGUAR study to compare outcomes […]
Endologix LLC Receives FDA Breakthrough Device Designation for ChEVAS™ System
Investigational EVAS System Designed for Patients with Complex Abdominal Aortic Aneurysm IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a leader in the treatment of vascular disease, today announced the company’s ChEVAS™ (Chimney EndoVascular Aneurysm Sealing) System has been granted a Breakthrough Device Designation […]